Class information for:
Level 1: ANTIBODY DRUG CONJUGATE//GEMTUZUMAB OZOGAMICIN//MYLOTARG

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
11281 994 43.2 86%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
6 4 GASTROENTEROLOGY & HEPATOLOGY//ONCOLOGY//SURGERY 1371034
416 3       NEUROENDOCRINE TUMORS//CARCINOID//SMALL CELL CARCINOMA 28897
808 2             RADIOIMMUNOTHERAPY//NUCLEAR MEDICINE AND BIOLOGY//ANTIBODY DRUG CONJUGATE 12023
11281 1                   ANTIBODY DRUG CONJUGATE//GEMTUZUMAB OZOGAMICIN//MYLOTARG 994

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 ANTIBODY DRUG CONJUGATE authKW 2767757 18% 52% 174
2 GEMTUZUMAB OZOGAMICIN authKW 1378733 7% 61% 74
3 MYLOTARG authKW 355091 2% 68% 17
4 DRUG TO ANTIBODY RATIO authKW 307181 1% 100% 10
5 CALICHEAMICIN authKW 294471 2% 46% 21
6 IMMUNOCONJUGATE authKW 278871 5% 20% 45
7 MAYTANSINOID authKW 219410 1% 71% 10
8 ANTIBODY DRUG CONJUGATE ADC authKW 218633 1% 65% 11
9 ANTIBODY DRUG CONJUGATES ADCS authKW 178719 1% 73% 8
10 CD33 authKW 165835 3% 20% 27

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Oncology 3476 31% 0% 313
2 Hematology 2130 15% 0% 146
3 Biochemical Research Methods 2000 16% 0% 155
4 Pharmacology & Pharmacy 796 19% 0% 184
5 Chemistry, Organic 729 14% 0% 135
6 Chemistry, Multidisciplinary 581 18% 0% 179
7 Medicine, Research & Experimental 434 9% 0% 88
8 Chemistry, Medicinal 359 6% 0% 63
9 Biochemistry & Molecular Biology 191 16% 0% 157
10 Chemistry, Analytical 161 7% 0% 69

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 PRECLIN TRANSLAT PHARMACOKINET PHARMACOD 109705 1% 71% 5
2 PRECLIN TRANSLAT PHARMACOKINET PHARMACODYNAM 92154 0% 100% 3
3 BIOORGAN MASS SPE OMETRY LSMBO 71666 1% 33% 7
4 BIOCONJUGATES DISCOVERY DEV 69114 0% 75% 3
5 FUNCT CHEMOSYST UMR 7199 69114 0% 75% 3
6 BIOANALYT SCI LCMS 61436 0% 100% 2
7 BIOL P IMMUNOL 61436 0% 100% 2
8 BIOL DISCOVERY CALIF 52651 1% 29% 6
9 PROT ANALYT CHEM 37465 1% 10% 12
10 PRECLIN THER EUT 36562 1% 24% 5

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 BIOCONJUGATE CHEMISTRY 49928 9% 2% 90
2 MABS 30374 3% 4% 27
3 BIOANALYSIS 7109 2% 1% 18
4 MOLECULAR CANCER THERAPEUTICS 6758 3% 1% 30
5 AAPS JOURNAL 4568 1% 1% 13
6 EXPERT OPINION ON BIOLOGICAL THERAPY 4220 2% 1% 17
7 CLINICAL LYMPHOMA 3606 0% 3% 4
8 CLINICAL CANCER RESEARCH 3429 4% 0% 41
9 MOLECULAR PHARMACEUTICS 1889 1% 0% 14
10 LEUKEMIA 1762 2% 0% 21

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 ANTIBODY DRUG CONJUGATE 2767757 18% 52% 174 Search ANTIBODY+DRUG+CONJUGATE Search ANTIBODY+DRUG+CONJUGATE
2 GEMTUZUMAB OZOGAMICIN 1378733 7% 61% 74 Search GEMTUZUMAB+OZOGAMICIN Search GEMTUZUMAB+OZOGAMICIN
3 MYLOTARG 355091 2% 68% 17 Search MYLOTARG Search MYLOTARG
4 DRUG TO ANTIBODY RATIO 307181 1% 100% 10 Search DRUG+TO+ANTIBODY+RATIO Search DRUG+TO+ANTIBODY+RATIO
5 CALICHEAMICIN 294471 2% 46% 21 Search CALICHEAMICIN Search CALICHEAMICIN
6 IMMUNOCONJUGATE 278871 5% 20% 45 Search IMMUNOCONJUGATE Search IMMUNOCONJUGATE
7 MAYTANSINOID 219410 1% 71% 10 Search MAYTANSINOID Search MAYTANSINOID
8 ANTIBODY DRUG CONJUGATE ADC 218633 1% 65% 11 Search ANTIBODY+DRUG+CONJUGATE+ADC Search ANTIBODY+DRUG+CONJUGATE+ADC
9 ANTIBODY DRUG CONJUGATES ADCS 178719 1% 73% 8 Search ANTIBODY+DRUG+CONJUGATES+ADCS Search ANTIBODY+DRUG+CONJUGATES+ADCS
10 CD33 165835 3% 20% 27 Search CD33 Search CD33

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 JACKSON, DY , (2016) PROCESSES FOR CONSTRUCTING HOMOGENEOUS ANTIBODY DRUG CONJUGATES.ORGANIC PROCESS RESEARCH & DEVELOPMENT. VOL. 20. ISSUE 5. P. 852 -866 71 85% 1
2 BECK, A , TERRAL, G , DEBAENE, F , WAGNER-ROUSSET, E , MARCOUX, J , JANIN-BUSSAT, MC , COLAS, O , VAN DORSSELAER, A , CIANFERANI, S , (2016) CUTTING-EDGE MASS SPECTROMETRY METHODS FOR THE MULTI-LEVEL STRUCTURAL CHARACTERIZATION OF ANTIBODY-DRUG CONJUGATES.EXPERT REVIEW OF PROTEOMICS. VOL. 13. ISSUE 2. P. 157 -183 81 44% 14
3 SHEFET-CARASSO, L , BENHAR, I , (2015) ANTIBODY-TARGETED DRUGS AND DRUG RESISTANCE-CHALLENGES AND SOLUTIONS.DRUG RESISTANCE UPDATES. VOL. 18. ISSUE . P. 36 -46 85 56% 10
4 PEREZ, HL , CARDARELLI, PM , DESHPANDE, S , GANGWAR, S , SCHROEDER, GM , VITE, GD , BORZILLERI, RM , (2014) ANTIBODY-DRUG CONJUGATES: CURRENT STATUS AND FUTURE DIRECTIONS.DRUG DISCOVERY TODAY. VOL. 19. ISSUE 7. P. 869 -881 58 62% 74
5 SINGH, SK , LUISI, DL , PAK, RH , (2015) ANTIBODY-DRUG CONJUGATES: DESIGN, FORMULATION AND PHYSICOCHEMICAL STABILITY.PHARMACEUTICAL RESEARCH. VOL. 32. ISSUE 11. P. 3541 -3571 85 59% 3
6 LU, J , JIANG, F , LU, AP , ZHANG, G , (2016) LINKERS HAVING A CRUCIAL ROLE IN ANTIBODY-DRUG CONJUGATES.INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. VOL. 17. ISSUE 4. P. - 63 77% 0
7 CARTER, PJ , SENTER, PD , (2008) ANTIBODY-DRUG CONJUGATES FOR CANCER THERAPY.CANCER JOURNAL. VOL. 14. ISSUE 3. P. 154-169 76 52% 181
8 POLAKIS, P , (2016) ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY.PHARMACOLOGICAL REVIEWS. VOL. 68. ISSUE 1. P. 3 -19 47 48% 17
9 ROSS, PL , WOLFE, JL , (2016) PHYSICAL AND CHEMICAL STABILITY OF ANTIBODY DRUG CONJUGATES: CURRENT STATUS.JOURNAL OF PHARMACEUTICAL SCIENCES. VOL. 105. ISSUE 2. P. 391 -397 46 78% 3
10 SANDERSON, RJ , NICHOLAS, ND , LEE, CB , HENGEL, SM , LYON, RP , BENJAMIN, DR , ALLEY, SC , (2016) ANTIBODY-CONJUGATED DRUG ASSAY FOR PROTEASE-CLEAVABLE ANTIBODY-DRUG CONJUGATES.BIOANALYSIS. VOL. 8. ISSUE 1. P. 55 -63 32 91% 7

Classes with closest relation at Level 1


Rank Class id link
1 35662 A33 ANTIGEN//ADHESION REGULATING MOLECULE 1//ADRM1
2 25493 LEUKEMIA STEM CELLS//LEUKEMIC STEM CELLS//CD123
3 30646 OSTEOACTIVIN//GPNMB//GLYCOPROTEIN NON METASTATIC MELANOMA PROTEIN B
4 25496 AML IN CHILDREN//BFM AML GRP//HONG KONG PAEDIAT HAEMATOL ONCOL STUDY GRP
5 6520 IMMUNOTOXIN//GELONIN//RICIN A CHAIN
6 2563 TRASTUZUMAB//LAPATINIB//PERTUZUMAB
7 33929 TUBULYSIN//PYRROLO 1 5 BENZOXAZEPINES//PBOX
8 3192 BIOORTHOGONAL REACTIONS//BIOORTHOGONAL CHEMISTRY//NONCANONICAL AMINO ACIDS
9 10008 CD20//OFATUMUMAB//OBINUTUZUMAB
10 4824 AGALACTOSYL IGG//MABS//PROT ANALYT CHEM

Go to start page